Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label single-arm study of BPI-7711 capsules in EGFR T790M-positive metastatic or recurrent non-small cell lung cancer
CTR20190214Phase 2Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezivertinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Jul 2019; status: active.
02
Drugs
rezivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190214.